| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics |
Cancer Research Program, Garvan Institute of Medical Research, St. Vincent’s Hospital, Sydney, New South Wales 2010, Australia
The proto-oncogene c-myc is up-regulated by estrogen stimulation of hormone-dependent breast cancer cells and is frequently overexpressed in breast and other cancers. Therapeutic interventions that inhibit c-Myc expression have been extensively investigated, including antisense oligonucleotides that have high specificity and potential clinical application. This investigation compared antiestrogen-mediated growth arrest with the molecular events after repression of c-Myc expression in MCF-7 breast cancer cells using an antisense oligonucleotide. We show that the decreased cellular proliferation of MCF-7 cells after direct inhibition of c-Myc is a consequence of inhibition of cyclin D1 expression, subsequent redistribution of p21WAF1/CIP1 from cyclin D1-Cdk4 to cyclin E-Cdk2 complexes, and a decline in cyclin E-Cdk2 enzymatic activity. Simultaneous repression of p21WAF1/CIP1 can attenuate the growth-inhibitory effects of reduced c-Myc expression emphasizing the importance of this cyclin-dependent kinase (CDK) inhibitor in growth arrest. These molecular events are similar to the initial changes in cyclin gene expression, CDK complex formation and CDK activity seen after antiestrogen (ICI 182780)-mediated growth inhibition of MCF-7 cells, which suggests that the down-regulation of c-Myc by ICI 182780 is a primary event that culminates in cell cycle arrest.
This article has been cited by other articles:
|
|
 |
|
  N. Levy, D. Tatomer, C. B. Herber, X. Zhao, H. Tang, T. Sargeant, L. J. Ball, J. Summers, T. P. Speed, and D. C. Leitman Differential Regulation of Native Estrogen Receptor-Regulatory Elements by Estradiol, Tamoxifen, and Raloxifene Mol. Endocrinol., February 1, 2008; 22(2): 287 - 303. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Verykokakis, C. Papadaki, E. Vorgia, L. Le Gallic, and G. Mavrothalassitis The RAS-dependent ERF Control of Cell Proliferation and Differentiation Is Mediated by c-Myc Repression J. Biol. Chem., October 12, 2007; 282(41): 30285 - 30294. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W-D Han, Y-L Zhao, Y-G Meng, L Zang, Z-Q Wu, Q Li, Y-L Si, K Huang, J-M Ba, H Morinaga, et al. Estrogenically regulated LRP16 interacts with estrogen receptor {alpha} and enhances the receptor's transcriptional activity Endocr. Relat. Cancer, September 1, 2007; 14(3): 741 - 753. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Drabsch, H. Hugo, R. Zhang, D. H. Dowhan, Y. R. Miao, A. M. Gewirtz, S. C. Barry, R. G. Ramsay, and T. J. Gonda Mechanism of and requirement for estrogen-regulated MYB expression in estrogen-receptor-positive breast cancer cells PNAS, August 21, 2007; 104(34): 13762 - 13767. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A M Lorincz and S Sukumar Molecular links between obesity and breast cancer. Endocr. Relat. Cancer, June 1, 2006; 13(2): 279 - 292. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J Butt, C. M McNeil, E. A Musgrove, and R. L Sutherland Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin E Endocr. Relat. Cancer, July 1, 2005; 12(Supplement_1): S47 - S59. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Martineti, L. Picariello, I. Tognarini, S. C. Sala, A. Gozzini, C. Azzari, C. Mavilia, A. Tanini, A. Falchetti, G. Fiorelli, et al. ER{beta} is a potent inhibitor of cell proliferation in the HCT8 human colon cancer cell line through regulation of cell cycle components Endocr. Relat. Cancer, June 1, 2005; 12(2): 455 - 469. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. R. Devi, T. M. Beer, C. L. Corless, V. Arora, D. L. Weller, and P. L. Iversen In vivo Bioavailability and Pharmacokinetics of a c-MYC Antisense Phosphorodiamidate Morpholino Oligomer, AVI-4126, in Solid Tumors Clin. Cancer Res., May 15, 2005; 11(10): 3930 - 3938. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Mukherjee and S. E. Conrad c-Myc Suppresses p21WAF1/CIP1 Expression during Estrogen Signaling and Antiestrogen Resistance in Human Breast Cancer Cells J. Biol. Chem., May 6, 2005; 280(18): 17617 - 17625. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Gauduchon, F. Gouilleux, S. Maillard, V. Marsaud, J.-M. Renoir, and B. Sola 4-Hydroxytamoxifen Inhibits Proliferation of Multiple Myeloma Cells In vitro through Down-Regulation of c-Myc, Up-Regulation of p27Kip1, and Modulation of Bcl-2 Family Members Clin. Cancer Res., March 15, 2005; 11(6): 2345 - 2354. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. M. Trost, E. U. Lausch, S. A. Fees, S. Schmitt, T. Enklaar, D. Reutzel, L. R. Brixel, P. Schmidtke, M. Maringer, I. B. Schiffer, et al. Premature Senescence Is a Primary Fail-safe Mechanism of ERBB2-Driven Tumorigenesis in Breast Carcinoma Cells Cancer Res., February 1, 2005; 65(3): 840 - 849. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Osborne, P. Wilson, and D. Tripathy Oncogenes and Tumor Suppressor Genes in Breast Cancer: Potential Diagnostic and Therapeutic Applications Oncologist, July 1, 2004; 9(4): 361 - 377. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Strom, J. Hartman, J. S. Foster, S. Kietz, J. Wimalasena, and J.-A. Gustafsson Estrogen receptor {beta} inhibits 17{beta}-estradiol-stimulated proliferation of the breast cancer cell line T47D PNAS, February 10, 2004; 101(6): 1566 - 1571. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Paruthiyil, H. Parmar, V. Kerekatte, G. R. Cunha, G. L. Firestone, and D. C. Leitman Estrogen Receptor {beta} Inhibits Human Breast Cancer Cell Proliferation and Tumor Formation by Causing a G2 Cell Cycle Arrest Cancer Res., January 1, 2004; 64(1): 423 - 428. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Carroll, D. K. Lynch, A. Swarbrick, J.-M. Renoir, B. Sarcevic, R. J. Daly, E. A. Musgrove, and R. L. Sutherland p27Kip1 Induces Quiescence and Growth Factor Insensitivity in Tamoxifen-treated Breast Cancer Cells Cancer Res., August 1, 2003; 63(15): 4322 - 4326. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. H. Wang, X. Y. Yang, X. Zhang, K. Mihalic, W. Xiao, and W. L. Farrar The cis Decoy against the Estrogen Response Element Suppresses Breast Cancer Cells via Target Disrupting c-fos not Mitogen-activated Protein Kinase Activity Cancer Res., May 1, 2003; 63(9): 2046 - 2051. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Saito-Ohara, I. Imoto, J. Inoue, H. Hosoi, A. Nakagawara, T. Sugimoto, and J. Inazawa PPM1D Is a Potential Target for 17q Gain in Neuroblastoma Cancer Res., April 15, 2003; 63(8): 1876 - 1883. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. F. Doisneau-Sixou, P. Cestac, S. Chouini, J. S. Carroll, A. D. Hamilton, S. M. Sebti, M. Poirot, P. Balaguer, J.-C. Faye, R. L. Sutherland, et al. Contrasting Effects of Prenyltransferase Inhibitors on Estrogen-Dependent Cell Cycle Progression and Estrogen Receptor-Mediated Transcriptional Activity in MCF-7 Cells Endocrinology, March 1, 2003; 144(3): 989 - 998. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
